Oncoinvent ASA (7BG)
FSX
Closed
Oct 1, 2026
Day's Range
7.7052 wk Range
0.01000Overview - 7BG - Oncoinvent ASA
Key Statistics
Valuation
Enterprise Value
-5.92M
P/E (Trailing)
‪-0.08‬
Price / Sales (TTM)
‪1.69‬
Price / Book
‪5.52‬
EV / EBITDA
‪0.38‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-841.07%‬
Return on Assets
‪-94.21%‬
Return on Equity
‪-228.06%‬
Ownership
Shares Outstanding
4.47M
Float
2.44M
Held by Insiders
‪23.07%‬
Held by Institutions
‪38.69%‬
Price stats
50-Day Avg
‪7.11‬
200-Day Avg
‪4.31‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 7BG - Oncoinvent ASA
Peers - 7BG - Oncoinvent ASA
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 7BGFSXOncoinvent ASA45.67MMarket Cap+58.39%52-week change-0.08P/E (Trailing)‪0.00%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 7BG - Oncoinvent ASA
About
Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
